Quick summary
Collagen Type II is the primary cartilage protein, studied as hydrolyzed form for amino acid supply and as undenatured UC-II to induce oral tolerance against cartilage autoimmunity. A 1993 Science paper showed UC-II suppressed RA symptoms.
Overview
Collagen Type II is the primary structural protein of articular cartilage, constituting the major fibrillar component of the cartilaginous ECM. Unlike Types I and III, it is rarely consumed as a hydrolysate for general skin support. Instead, Type II collagen is studied in two distinct forms: hydrolyzed (for cartilage amino acid supply) and undenatured (UC-II, which preserves native triple-helix epitopes). UC-II at low doses induces oral tolerance — a gut-mediated immune re-education that reduces autoimmune cartilage attack in arthritis.
Mechanism of action
Undenatured Type II collagen (UC-II) at microgram doses interacts with Peyer's patches in the gut-associated lymphoid tissue. This triggers induction of regulatory T cells (Tregs) that specifically recognize Type II collagen epitopes. When these Tregs encounter Type II collagen in joint cartilage, they secrete anti-inflammatory cytokines (TGF-β, IL-4, IL-10) that suppress local immune-mediated cartilage destruction. This oral tolerance mechanism is distinct from the amino acid supplementation approach used with hydrolyzed collagen, requiring far lower doses and native epitope preservation.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| joint health / oral tolerance (UC-II, undenatured) | oral | 40–40 mg | once daily (on empty stomach) | UC-II oral tolerance requires very low doses — 40 mg/day is the established effective dose. Higher doses may defeat the oral tolerance mechanism. |
| joint support (hydrolyzed collagen type II) | oral | 5000–10000 mg | once daily | Hydrolyzed form used at higher doses for amino acid supply; different mechanism from UC-II. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
A landmark 1993 Science paper demonstrated that oral UC-II administration suppressed rheumatoid arthritis symptoms in a human trial (n=60). Subsequent animal and human studies confirm UC-II reduces osteoarthritis pain, improves joint function, and decreases inflammatory cytokines. A 2025 Annals of Medicine review consolidates current evidence for knee OA. Hydrolyzed Type II collagen supplements have also shown benefits in joint pain reduction in multiple RCTs, through a different (amino acid supply) mechanism.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Collagen Type II for synergistic effects.
Legal status
Available OTC as a dietary supplement (both UC-II and hydrolyzed forms). UC-II is a patented ingredient. Not regulated as a pharmaceutical.
Sourcing & access
Research compound
Collagen Type II is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Collagen Type II is the major fibrillar structural protein of articular cartilage, constituting the primary component of the cartilaginous extracellular matrix. Unlike Types I and III, it is studied primarily for joint health rather than skin support, in two distinct forms: hydrolyzed (for amino acid supply) and undenatured UC-II (for immune modulation via the oral tolerance mechanism).
Undenatured Type II collagen (UC-II) at microgram doses interacts with Peyer's patches in the gut-associated lymphoid tissue. This triggers induction of regulatory T cells that specifically recognize Type II collagen epitopes. When these Tregs encounter Type II collagen in joint cartilage, they secrete anti-inflammatory cytokines (TGF-beta, IL-4, IL-10) that suppress local immune-mediated cartilage destruction, reducing arthritis symptoms.
The established effective dose for UC-II oral tolerance is 40 mg once daily taken on an empty stomach. This low dose is critical — higher doses may overwhelm the oral tolerance mechanism and actually defeat the intended immune modulation. For hydrolyzed collagen Type II supplements intended to supply cartilage-building amino acids, doses of 5,000 to 10,000 mg daily are typically used through a completely different mechanism.
Collagen Type II supplements are generally well tolerated as OTC dietary supplements. The most common side effect is mild GI discomfort, particularly at higher hydrolyzed doses. A theoretical concern exists regarding immune modulation in immunocompromised patients using UC-II at oral tolerance doses, though this has not been reported as a clinical problem. A landmark 1993 Science paper trial (n=60) confirmed tolerability.
Research references
- Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trialClinicalTrials.gov
- Undenatured type II collagen (UC-II) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteersClinicalTrials.gov
- Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled studyClinicalTrials.gov
- 24-week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint painClinicalTrials.gov
- A double-blind, placebo-controlled, randomised, clinical study on the effectiveness of collagen peptide on osteoarthritisClinicalTrials.gov